Home > Boards > US Listed > Medical - Healthcare > CorMedix Inc (CRMD)

CorMedix Inc. to Begin Trading on the Nasdaq

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Expresso123 Member Profile
 
Followed By 8
Posts 926
Boards Moderated 0
Alias Born 07/04/17
160x600 placeholder
CorMedix Inc. Completes Sale of $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Progra... GlobeNewswire Inc. - 6/10/2021 8:30:00 AM
CorMedix Inc. to Participate in Fireside Chat at the JMP Securities Life Sciences Conference GlobeNewswire Inc. - 6/9/2021 8:30:00 AM
CorMedix Inc. to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire Inc. - 5/27/2021 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 4:47:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/20/2021 4:19:15 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/20/2021 4:17:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/19/2021 5:41:04 PM
CorMedix slumps 20% despite a surge in Q1 revenue Seeking Alpha - 5/14/2021 3:34:59 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/14/2021 6:03:51 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2021 4:37:20 PM
CorMedix EPS misses by $0.02, beats on revenue Seeking Alpha - 5/13/2021 4:23:02 PM
CorMedix names Thomas Nusbickel chief commercial officer Seeking Alpha - 5/13/2021 8:45:40 AM
CorMedix Inc. Announces Appointment of Chief Commercial Officer GlobeNewswire Inc. - 5/13/2021 8:30:00 AM
CorMedix Inc. to Participate at the 7th Annual Truist Securities Life Sciences Summit GlobeNewswire Inc. - 4/28/2021 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/15/2021 10:04:26 AM
CorMedix meets FDA to resolve issues in CRL for DefenCath Seeking Alpha - 4/14/2021 9:28:56 AM
CorMedix Has Meeting With FDA on DefenCath Catheter Lock Solution NDA GlobeNewswire Inc. - 4/14/2021 9:00:00 AM
CorMedix Inc. to Present at the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire Inc. - 4/7/2021 8:30:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/30/2021 5:05:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/30/2021 5:04:06 PM
CorMedix EPS beats by $0.03, beats on revenue Seeking Alpha - 3/30/2021 4:07:54 PM
CorMedix Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update GlobeNewswire Inc. - 3/30/2021 4:05:00 PM
CorMedix Approved to Sell $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program GlobeNewswire Inc. - 3/15/2021 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/12/2021 4:43:32 PM
CorMedix Inc. Announces Contract Extension of Liz Masson-Hurlburt as Executive Vice President and Head of Clinical Operations... GlobeNewswire Inc. - 3/11/2021 8:30:00 AM
Expresso123   Friday, 01/22/21 08:12:45 AM
Re: None
Post # of 2443 
CorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange
BERKELEY HEIGHTS, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has been approved for listing on the Nasdaq Global Market. The company’s shares will continue to trade under its current symbol “CRMD”. Trading on the Nasdaq Global Market is expected to commence on Tuesday, February 2, 2021. The Company’s shares of common stock will continue to trade on the NYSE American until the close of the market on Monday, February 1, 2021.
Khoso Baluch, CorMedix CEO commented, “We are excited to have Nasdaq as our new exchange partner. As a late stage biopharma company, we feel that Nasdaq is a natural fit and already includes many of our peers in the space. With the February 28, 2021 PDUFA date for completion of FDA’s review of the Defencath NDA on the horizon, the year ahead is likely to hold significant growth for CorMedix as we set our sights on becoming a commercial entity in the US. We believe this move will further enhance our visibility in the marketplace, expose our company to a larger audience of institutional investors and ultimately increase liquidity and shareholder value.”


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences